In accordance with these results, other studies have found that MLH1 and MSH2 carriers have a higher risk of developing CRC than MLH6 carriers (25), as well as PMS2 carriers (14–16), which could also be explained by the more rapid CRC development amongst MLH1 and MSH2 carriers (6). This evidence concerns the gene PMS2 and colorectal carcinoma.